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Background—-Macrophage-mediated chronic inﬂammation is mechanistically linked to insulin resistance and atherosclerosis.
Although arginase I is considered antiinﬂammatory, the role of arginase II (Arg-II) in macrophage function remains elusive. This
study characterizes the role of Arg-II in macrophage inﬂammatory responses and its impact on obesity-linked type II diabetes
mellitus and atherosclerosis.
Methods and Results—-In human monocytes, silencing Arg-II decreases the monocytes’ adhesion to endothelial cells and their
production of proinﬂammatory mediators stimulated by oxidized low-density lipoprotein or lipopolysaccharides, as evaluated by
real-time quantitative reverse transcription-polymerase chain reaction and enzyme-linked immunosorbent assay. Macrophages
differentiated from bone marrow cells of Arg-II–deﬁcient (Arg-II−/−) mice express lower levels of lipopolysaccharide-induced proin-
ﬂammatory mediators than do macrophages of wild-type mice. Importantly, reintroducing Arg-II cDNA into Arg-II−/− macrophages
restores the inﬂammatory responses, with concomitant enhancement of mitochondrial reactive oxygen species. Scavenging of re-
active oxygen species by N-acetylcysteine prevents the Arg-II–mediated inﬂammatory responses. Moreover, high-fat diet–induced
inﬁltration of macrophages in various organs and expression of proinﬂammatory cytokines in adipose tissue are blunted in Arg-
II−/− mice. Accordingly, Arg-II−/− mice reveal lower fasting blood glucose and improved glucose tolerance and insulin sensitivity.
Furthermore, apolipoprotein E (ApoE)–deﬁcient mice with Arg-II deﬁciency (ApoE−/−Arg-II−/−) display reduced lesion size with char-
acteristics of stable plaques, such as decreased macrophage inﬂammation and necrotic core. In vivo adoptive transfer experiments
reveal that fewer donor ApoE−/−Arg-II−/− than ApoE−/−Arg-II+/+ monocytes inﬁltrate into the plaque of ApoE−/−Arg-II+/+ mice.
Conversely, recipient ApoE−/−Arg-II−/− mice accumulate fewer donor monocytes than do recipient ApoE−/−Arg-II+/+ animals.
Conclusions—-Arg-II promotesmacrophage proinﬂammatory responses throughmitochondrial reactive oxygen species, contributing
to insulin resistance and atherogenesis. Targeting Arg-II represents a potential therapeutic strategy in type II diabetes mellitus and
atherosclerosis. ( J Am Heart Assoc. 2012;1:e000992 doi: 10.1161/JAHA.112.000992.)
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M acrophage-mediated chronic inﬂammation is an im-portant mechanism for pathogenesis of obesity-
associated insulin resistance, type II diabetes mellitus, and
atherosclerosis.1–5 Studies in recent years have provided evi-
dence that macrophages are heterogeneous and undergo het-
erogeneous phenotypic changes, depending on microenviron-
mental stimuli.1,6 M1 and M2 macrophages are 2 extremes
of the cell phenotype spectrum.6 M1 macrophages can be
induced by microbial agents like lipopolysaccharides (LPS), ox-
idized low-density lipoproteins (oxLDL), and T helper cell type
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1 (Th1) cytokines (eg, interferon-γ ). The M1 phenotype is as-
sociated with increased production of chemoattractants, such
as monocyte chemoattractant protein (MCP) 1, and of numer-
ous proinﬂammatory cytokines, including interleukin (IL) 6 and
tumor necrosis factor (TNF) α, and is linked to inﬂammatory
diseases, such as obesity-associated insulin resistance and
atherosclerosis.6 In contrast, M2 macrophages are triggered
by the Th2 cytokines (eg, IL4 or IL13), are characterized by the
production of antiinﬂammatory cytokines such as IL10, and
are considered to participate in resolution of the inﬂammatory
responses.7,8
Evidence recently has been presented that reactive oxy-
gen species (ROS) such as superoxide anion (O2•−) and hy-
drogen peroxide (H2O2), especially mitochondrial ROS, are
important signals that provoke elevated production of proin-
ﬂammatory cytokines in monocytes/macrophages.9–11. Mito-
chondrial O2•− is converted to H2O2 by mitochondrial su-
peroxide dismutase-2, and H2O2 is further catalyzed to H2O
and O2 by catalase.12 ROS are defense mechanisms and
play an essential role in immune responses to pathogens,
but they also contribute to the pathophysiology of inﬂam-
matory diseases, including type II diabetes mellitus and
atherosclerosis.13,14
Among other genes, arginase has been demonstrated to
be involved in macrophage inﬂammatory responses through
regulation of inducible nitric oxide synthase (iNOS).15 The un-
derlying mechanism is attributed to depletion of speciﬁc in-
tracellular L-arginine pools for NOS by metabolizing L-arginine
to L-ornithine and urea.15 There are 2 isoenzymes of arginase,
arginase I (Arg-I) and arginase II (Arg-II), which are encoded
by different genes.16 Whereas Arg-I is a cytoplasmic enzyme
and primarily functions in the urea cycle involved in ammo-
nia detoxiﬁcation in the liver, Arg-II is located in mitochondria
and is widely expressed in extrahepatic tissues, particularly the
kidney.16 Macrophages express both Arg-I and Arg-II.17 Numer-
ous studies have shown that the enhanced expression of Arg-I
in M2 cells limits the bioavailability of intracellular L-arginine
for excessive nitric oxide production from iNOS and dampens
inﬂammation and tissue damage,18–20 contributing to the an-
tiinﬂammatory functions of M2 cells.21,22 Speciﬁc targeting
of Arg-I in macrophages has been shown to suppress clear-
ance of intracellular pathogens by decreasing nitric oxide
production.23 In contrast to Arg-I, only a few studies have
attempted to elucidate the role of Arg-II in macrophage inﬂam-
matory responses. One study proposed that Arg-II plays a role
in antiinﬂammatory responses on the basis of the association
between Arg-II and liver X receptor in macrophages.24 Another
study observed that bone marrow–derived macrophages sub-
jected to proinﬂammatory stimuli express Arg-II exclusively
and that the accumulation of Arg-II–expressing macrophages
is associated with advanced atherosclerotic lesions, which
suggests a proinﬂammatory role of Arg-II in macrophages.17
The results from these studies yielded completely opposite
conclusions. Moreover, evidence for a functional role of Arg-
II in macrophages is lacking. The effect of Arg-II gene dis-
ruption on macrophage inﬂammation in vivo in a chronic in-
ﬂammatory disease model, such as type II diabetes melli-
tus and atherogenesis, has not been investigated, although
treatment of apolipoprotein E–deﬁcient (ApoE−/−) mice with
nonspeciﬁc arginase inhibitors has been shown to reduce
atherosclerosis.25
Our study is therefore focused on characterization of
the functions of Arg-II in regulation of macrophage inﬂam-
matory responses and of the underlying molecular mecha-
nisms, by means of speciﬁc genetic approaches. Moreover,
the impact of the genetic targeted disruption of Arg-II on
pathogenesis of chronic inﬂammatory diseases (ie, obesity-
linked type II diabetes mellitus and atherosclerosis) also is
studied.
Methods
Materials
Reagents were purchased or obtained from the following
sources: Normal chow (NC; energy content: 12% fat, 28%
protein, and 60% carbohydrate) was purchased from UAR,
Epinay sur Orge, France. A high-fat diet (HF; energy con-
tent: 55% fat, 21% protein, and 24% carbohydrate; Harlan
Teklad TD 93075) and a high-cholesterol diet (HC; energy
content: 42.6% fat, 15.5% protein, and 41.9% carbohydrate;
1.3% cholesterol; Harlan Teklad TD.02828) were from Har-
lan, Horst, the Netherlands. LPS, thioglycollate medium, N-
acetylcysteine (NAC), 2′,7′-dichloroﬂuorescein (H2DCF), pro-
pidium iodide solution, and anti-tubulin (T5168) monoclonal
antibody were from Sigma (Buchs, Switzerland). Hoechst
33342 Stain was from ThermoFisher Scientiﬁc (Wohlen,
Switzerland). Recombinant human TNFα was purchased
from Brunschwig (Basel, Switzerland). Human oxLDL was
a product of INTRACEL and was purchased from Chemie
Brunschwig AG (Basel, Switzerland). Anti–Arg-I antibody
(#610708) was from BD Transduction Laboratories (Allschwil,
Switzerland), and anti–Arg-II antibody (sc-20151) was from
Santa Cruz (Nunningen, Switzerland). Anti-F4/80 (MCA497G)
and anti-CD11c (MCA1369EL) were from AbD Serotec
(Du¨sseldorf, Germany). Rabbit anti-MMP14 (ab51074) was
from Abcam (Cambridge, UK). Rabbit anti-iNOS (#06-573) was
from Upstate (Luzern, Switzerland). IRDye 800–conjugated
goat anti–rabbit IgG F(c) was purchased from LI-COR
GmbH (Bad Homburg, Germany). CFDA-SE (carboxyﬂuores-
cein diacetate, succinimidyl ester), MitoSox, Alexa Fluor
680–conjugated anti–mouse IgG (H+L), Alexa Fluor 488–
conjugated anti-hamster, and Alexa Fluor 546–conjugated
anti-rat and anti-rabbit IgG were from Invitrogen (Lubioscience,
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Luzern, Switzerland). Alexa Fluor 647–conjugated anti-CD11b
antibody was from eBioscience (Vienna, Austria).
Animals
The Arg-II–deﬁcient mice (Arg-II−/−) were kindly provided by
Dr William O’Brien26 and were backcrossed to C57BL/6J more
than 8 generations. Genotyping was performed by polymerase
chain reaction as previously described.26 The wild-type and
Arg-II−/− offspring from hetero/hetero crossing were inter-
bred to obtain wild-type and Arg-II−/− mice, respectively, for
experiments. Starting at the age of 7 weeks, the male wild-
type and Arg-II−/− mice were given free access for 14 weeks
to either a normal chow (NC) or a high-fat (HF) diet. A glu-
cose tolerance test (GTT) and an insulin tolerance test (ITT)
were performed after 6 hours of fasting in the twelfth and thir-
teenth weeks of HF diet, respectively. After 14 weeks of HF,
animals were euthanized, followed by collection of blood, peri-
toneal macrophages, bone marrow, and tissues. The isolated
tissues either were subjected to immunoﬂuorescence staining
or were snap-frozen in liquid nitrogen and kept at −80◦C un-
til processed. The blood samples were collected after 6-hour
starvation.
The ApoE−/− mice (Jackson Laboratory, Bar Harbor,
Maine) and Arg-II−/− mice, both on a C57BL/6J background,
were interbred to obtain ApoE−/−Arg-II−/− mice. To ac-
celerate atherosclerotic lesion formation, 10-week-old male
ApoE−/−Arg-II+/+ and ApoE−/−Arg-II−/− mice were fed ei-
ther the HF diet or a high-cholesterol (HC) diet for 10 weeks.
At 20 weeks of age, animals were anesthetized with ketamine
(100 mg/kg IP) and xylazine (10 mg/kg IP), and the entire
aorta from the heart to the iliac bifurcation was removed and
dissected free from fat and adhering perivascular tissue. The
aortic roots were snap-frozen in Optimal Cutting Temperature
compound. The 7-μm-thick cryosections of the aortic roots
and the entire thoracic-abdominal aortas were stained with
Oil Red O to assess lesion size, and the size of the necrotic
core was evaluated by hematoxylin-eosine staining of parafﬁn-
embedded sections of the aortic arches. The sizes of the lesion
and the necrotic core were quantiﬁed with the ImageJ software
(US National Institutes of Health). At least 7 equally spaced
aortic root cryosections or 4 equally spaced arch-parafﬁn sec-
tions per mouse were evaluated. The blood samples were
collected after overnight starvation. Housing and animal ex-
perimentation were approved by the Swiss Federal Veterinary
Ofﬁce.
Generation of Recombinant Adenoviruses
Expressing Murine Arg-II and Short Hairpin RNA
Generation of recombinant adenovirus (rAd) expressingmurine
Arg-II driven by cytomegalovirus (CMV) promoter (rAd/CMV-
Arg-II) and short hairpin RNA (shRNA) targeting human Arg-
II (hArg-II) driven by the U6 promoter (rAd/U6-hArg-IIshRNA)
was carried out with the Gateway technology (Invitrogen
Life Technologies) according to the manufacturer’s instruc-
tions. rAd/CMV-bacterial β-galactosidase (LacZ) and rAd/U6-
LacZshRNA were used as controls for rAd/CMV-Arg-II and
rAd/U6-hArg-IIshRNA, respectively. The pCMV6 construct en-
coding the murine Arg-II was obtained from Origene. The hu-
man Arg-II targeting sequence for rAd/U6-hArg-IIshRNA is indi-
cated in boldface below (only the sense strand is shown):
CACCGCGAGTGCATTCCATCCTGAACGAATTCAGGATGGAATG
CACTCGC
Cell Culture and Adenoviral Transduction of
THP-1 Cells and Bone Marrow–Derived
Macrophages
Human umbilical vein endothelial cells were isolated from um-
bilical cords and cultivated as described.27 The human mono-
cytic cell line THP-1 (American Type Culture Collection) was
maintained in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal bovine serum (HIFBS).
Bone marrow–derived macrophages were prepared from
bone marrow–derived cells by incubation with 10% HIFBS-
RPMI, supplemented with 20% of L929-conditioned medium
containing macrophage colony–stimulating factor, for 6 to
7 days to induce differentiation. Treatments were carried out
after 6 hours of starvation in 0.2% bovine serumalbumin (BSA)–
RPMI.
For adenoviral transduction of THP-1 cells, 1×106 THP-
1 cells were harvested in 100 μL RPMI without HIFBS, and
400 μL virus was added. After incubation at 37◦C for 2 hours
with rotation, 2 mL 10% HIFBS-RPMI was added. At day 4 after
transduction, the transduced cells were serum-starved in 0.2%
BSA-RPMI for 6 hours before the experiments. For adenovi-
ral transduction of bone marrow–derived macrophages, bone
marrow–derived macrophages at day 6 or 7 after differentia-
tion were transduced with rAd at a multiplicity of infection of
100 and were further incubated in 10% HIFBS-RPMI without
L929-conditioned medium for 2 days. Cells were starved in
0.2% BSA-RPMI for 6 hours, and then they were either treated
with 0.1 μg/mL LPS or left untreated for 22 hours.
Immunoblotting Analysis
Cell extracts were prepared by lysing cells on ice for 15 min-
utes by the addition of lysis buffer containing 20 mmol/L
Tris.HCl, 138 mmol/L NaCl, 2.7 mmol/L KCl, pH 8.0, sup-
plemented with 5% glycerol, 1 mmol/L MgCl2, 1 mmol/L
CaCl2, 1 mmol/L sodium-o-vanadate, 20 μmol/L leupeptin,
18 μmol/L pepstatin, 1% NP-40, 5 mmol/L EDTA, and
20 mmol/L NaF. Cell debris and nuclei were removed by
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centrifugation at 10 000×g for 10 minutes at 4◦C. Protein
concentration was determined with the Bio-Rad DC Protein As-
say kit, according to the manufacturer’s instruction. Extracts
(40 μg) were subjected to SDS-PAGE and were electrophoret-
ically transferred to an Immobilon-P membrane (Millipore),
and the resultant membrane was incubated overnight with
the corresponding ﬁrst antibody at 4◦C, with gentle agitation
after blocking with 5% skimmed milk. The protein was then
decorated with corresponding anti-mouse (Alexa Fluor 680–
conjugated) or anti-rabbit (IRDye 800–conjugated) secondary
antibodies. Signals were visualizedwith Odyssey Infrared Imag-
ing System (LI-COR Biosciences). Quantiﬁcation of the signals
was performed in NIH Image 1.62 software.
Peritoneal Macrophage Harvest
Peritoneal macrophages were obtained and puriﬁed as de-
scribed previously.28 Peritoneal macrophages were harvested
with or without thioglycollate elicitation (2 mL of 4% aged thio-
glycollate medium per mouse, 3 to 4 days) for adhesion assay
or immunoblotting analysis, respectively. The macrophages
then were puriﬁed by magnetic cell sorting with CD11b mi-
crobeads and LS columns, according to the manufacturer’s
instructions (Miltenyi Biotec, Bergisch Gladbach, Germany).
Monocyte and Macrophage Adhesion Assay
The labeling of monocytes/macrophages and the adhesion
assay were performed as described previously.28 Brieﬂy, the
cultured THP-1 monocytes or puriﬁed peritoneal macrophages
were labeled with 5 μmol/L of CFDA-SE in phosphate-buffered
saline (PBS) at 37◦C for 8 minutes. The labeling was stopped
with 1mLheat-inactivated (56◦C×30 minutes) fetal calf serum
for 1 minute. The labeled macrophages (2×105 THP-1 or
1×105 thioglycollate-elicited murine peritoneal macrophages)
were then added to the activated human umbilical vein en-
dothelial cells that had been treated with 10 ng/mL TNFα
overnight in 12-well plates. After incubation for 15 minutes
at 37◦C, the cells were washed twice with PBS, and images
of adherent monocytes or macrophages were captured under
the ﬂuorescent microscope (5 different ﬁelds per sample). The
number of adherent monocytes or macrophages was counted
with the ImageJ software (US National Institutes of Health) by
a researcher who was blinded to the experimental protocols.
Adoptive Transfer
Twenty-week-old ApoE−/−Arg-II+/+ and ApoE−/−Arg-II−/−
mice that had received HC diet during the previous 10 weeks
were used for adoptive transfer experiments. Monocytes were
puriﬁed from the splenocytes of the donor mice by magnetic
cell sorting with CD11b microbeads and LS columns, accord-
ing to the manufacturer’s instructions (Miltenyi Biotec, Ber-
gisch Gladbach, Germany). Preparation of splenocytes was
performed as described previously.29 The purity of mono-
cytes was veriﬁed by ﬂow cytometry analysis after 1×106
cells were incubated with Alexa Fluor 647–conjugated anti-
CD11b antibody. The puriﬁed monocytes were labeled with
cell-permeable Hoechst 33342 Stain (4 μg/mL, 30 minutes)
in 10% HIFBS-RPMI (1×106 cells/mL). After being washed 3
times, the labeledmonocytes were resuspended at 2×106/mL
in 2% HIFBS-PBS. Labeled monocytes (1×106) in 500 μL of 2%
HIFBS-PBS were adoptively transferred by intravenous injec-
tion into the tail veins of the recipient mice. Sixty hours after
transfer, animalswere anesthetizedwith ketamine (100mg/kg
IP) and xylazine (10 mg/kg IP) and euthanized. The aortic
roots were prepared and snap-frozen in Optimal Cutting Tem-
perature compound. The 7-μm-thick cryosections of the aor-
tic roots were ﬁxed with ice-cold methanol for 20 minutes,
followed by counterstaining with propidium iodide solution
(5 μg/mL, 5 minutes). The number of adoptively transferred
labeled monocytes in atherosclerotic plaques was visualized
and counted under LEICA’s DMI6000 Confocal microscope.
Ten equally spaced aortic root cryosections per mouse were
evaluated.
Tissue Immunoﬂuorescence Staining and
Confocal Microscopy
After deparafﬁnization in xylene, hydration in ethanol, and
antigen retrieval in citrate buffer (10 mmol/L, pH 6.5) in a
microwave oven, parafﬁn-embedded sections (7 μm) were
blocked with 2% BSA in PBS for 30 minutes and then were
incubated with the ﬁrst antibodies and subsequently with
ﬂuorescence-labeled secondary antibodies at room tempera-
ture, for 2 hours and 1 hour, respectively, followed by counter-
staining with 300 nmol/L DAPI (4’6-diamidino-2-phenyl-indole,
dihydrochloride, Invitrogen) for 2 minutes. The immunoﬂu-
orescence signals were visualized under LEICA’s DIM6000
Confocal microscope. The same procedure was applied for
immunoﬂuorescence staining of the 7-μm cryosections of
aortic roots, except that the sections were ﬁxed with either
0.4% paraformaldehyde (for anti-F4/80) or methanol (for anti-
CD11c and anti-MMP14).
Real-Time Quantitative Reverse Transcription
Polymerase Chain Reaction Analysis
Total RNA extraction and mRNA expression analysis by 2-step
real-time quantitative reverse-transcription polymerase chain
reaction (qRT-PCR) were performed as described previously.30
The mRNA expression levels of all genes were normalized
to the reference gene glyceraldehyde 3-phosphate dehydro-
genase (GAPDH). The primer sequences are summarized in
Table 1.
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Table 1. Primer Sequences for qRT-PCR
mF4/80F TGGCTGCCTCCCTGACTTTC
mF4/80R CAAGATCCCTGCCCTGCACT
mCD11cF GGAGGAGAACAGAGGTGCTG
mCD11cR CACCTGCTCCTGACACTCAA
mMCP1F AGCACCAGCCAACTCTCAC
mMCP1R TCTGGACCCATTCCTTCTTG
mTNFαF GGCAGGTCTACTTTGGAGTCATTGC
mTNFαR ACATTCGAGGCTCCAGTGAATTCGG
mIL6F GACAACCACGGCCTTCCCTA
mIL6R GCCTCCGACTTGTGAAGTGGT
miNOSF GGCAAACCCAAGGTCTACGTT
miNOSR TCGCTCAAGTTCAGCTTGGT
mArg-IIF CCCCTTTCTCTCGGGGACAGAA
mArg-IIR GAAAGGAAAGTGGCTGTCCA
mGAPDHF ACCCAGAAGACTGTGGATGG
mGAPDHR ACACATTGGGGGTAGGAACA
mMMP14 from Qiagen #QT01064308
hMCP1F GATCTCAGTGCAGAGGCTCG
hMCP1R TGCTTGTCCAGGTGGTCCAT
hTNFαF CCCAGGGACCTCTCTCTAATCA
hTNFαR GCTACAGGCTTGTCACTCGG
hIL6F GGCACTGGCAGAAAACAACC
hIL6R GCAAGTCTCCTCATTGAATCC
hArgIIF GGCTGAGGTGGTTAGCAGAG
hArgIIR CTGGCTGTCCATGGAGATTT
Primer sequences are of mouse (m) or human (h) origin.
Enzyme-Linked Immunosorbent Assay
The protein level of proinﬂammatory mediators in the condi-
tioned medium of RPMI containing 0.2% BSA was evaluated by
enzyme-linked immunosorbent assay with the use of the ELISA
MAX Deluxe from BioLegend, according to the manufacturer’s
instructions (Lucerna Chem AG, Luzern, Switzerland).
Detection of Mitochondrial O2•− and H2O2 in
Bone Marrow–Derived Macrophages
Mitochondrial O2•− and H2O2 levels were detected with ﬂu-
orescent dyes. For detection of mitochondrial O2•−, cells
were incubated with 5 μmol/L MitoSox in culture medium
for 10 minutes. For detection of H2O2, cells were washed with
PBS and incubated with 10 μmol/L 2′,7′-dichloroﬂuorescein
(H2DCF) in PBS for 25 minutes. After washing, images were
obtained with a Zeiss ﬂuorescence microscope. The intensity
of the ﬂuorescence was quantiﬁed by ImageJ software (US
National Institutes of Health) and normalized by cell number.
GTT and ITT
GTT and ITT were performed on mice that had been fasted for
6 hours. For GTT, animals were injected intraperitoneally with
glucose (1 g/kg), whereas for ITT, 0.5 U/kg human insulin
(Actrapid HM, Novo-Nordisk) was injected intraperitoneally.
Blood glucose was measured at 0, 15, 30, 45, 60, 90, and
120 minutes after intraperitoneal injection by a One-Touch
Glucose Monitoring System Ascensia Contour (Bayer).
Measurement of Blood Parameters
Blood samples were obtained by cardiac puncture after 6-hour
or overnight starvation for wild-type and Arg-II−/− mice or for
ApoE−/−Arg-II+/+ and ApoE−/−Arg-II−/− mice, respectively.
The measurement of the total blood cholesterol, triglycerides,
and insulin were performed by Services of the Metabolic Plat-
form at the Metabolic Evaluation Facility (MEF), Faculty of Biol-
ogy and Medicine, University of Lausanne, Switzerland. Blood
glucose was measured by a One-Touch Glucose Monitoring
System Ascensia Contour (Bayer).
Statistical Analysis
The Kolmogorov-Smirnov test was used to ﬁrst determine
whether the data deviated from Gaussian distributions. For
normally distributed values, statistical analysis was performed
with the Student t test for unpaired observations or analysis
of variance with Bonferroni post-test, and data are given as
mean ± standard error of the mean (SEM). For non–normally
distributed values, nonparametric statistical analysis was per-
formed with the Mann-Whitney test or the Kruskal-Wallis test
with Dunn’s multiple-comparison post-test, and data are ex-
pressed as medians with 25th and 75th percentiles. P≤0.05
is considered to indicate statistical difference. The “n” indi-
cates the number of individual animals used or the number of
individual experiments when conducted with cell lines.
Results
Arg-II Plays a Proinﬂammatory Role in
Macrophages
In accordance with previous reports,31 we show here that the
murine macrophage cell line RAW264.7, when stimulated with
LPS (0.1 μg/mL) to induce M1 phenotype activation, revealed
an enhanced expression of iNOS and Arg-II but not Arg-I (Fig-
ure 1A). Similarly, stimulation of the human monocyte cell
line THP-1 with LPS (0.1 μg/mL, 22 hours) upregulated Arg-II
but not Arg-I (Figure 1B). In contrast to the RAW264.7 cells,
no increase in iNOS level was observed in THP-1 cells (Fig-
ure 1B). Moreover, differentiation of THP-1 monocytes into
macrophages by the phorbol ester PMA (phorbol 12-myristate
13-acetate; 0.2 μmol/L for 3 days) also was accompanied by
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Figure 1. Upregulation of Arg-II but not of Arg-I in response to inﬂammatory activation and
differentiation of monocytes/macrophages. A, The murine macrophage cell line RAW264.7
was stimulated with LPS (0.1μg/mL) for the indicated time points (hours). The expression of
iNOS, Arg-I, and Arg-II was detected by Western blot. Protein lysates of murine liver (Li) and
kidney (Ki) were used as positive controls for Arg-I and Arg-II, respectively. Representative
blots from 3 independent experiments are shown. The graphs below the blots present
the quantiﬁcation of the signals. Values are medians, and error bars represent 25th and
75th percentiles. The Kruskal-Wallis test with Dunn’s multiple-comparison post-test was
performed. *P<0.05, **P<0.01 vs control. B and C, The human monocyte cell line THP-1
was either (B) activated with LPS (0.1 mg/mL, 22 h) or (C) differentiated into macrophages
with PMA (phorbol 12-myristate 13-acetate; 0.2 μmol/mL, 3 days).
increased Arg-II expression without detectable upregulation of
iNOS or Arg-I (Figure 1C). These results demonstrate that M1
activation and monocyte differentiation to macrophages are
accompanied by Arg-II but not Arg-I gene upregulation.
To determine whether Arg-II is involved in proinﬂammatory
functions of macrophages, THP-1 cells were transduced with
rAd carrying shRNA against human Arg-II (rAd/U6-Arg-IIshRNA),
and cell adhesion activity was assayed. Silencing of Arg-II, con-
ﬁrmed by immunoblotting (Figure 2A-a), decreased adhesion
activity of THP-1 cells onto human umbilical vein endothelial
cells (prestimulatedwith 10 ng/mL TNFα overnight to enhance
endothelial adhesion molecule expression) when compared to
control cells transduced with rAd/U6-LacZshRNA (Figure 2A-b
and 2A-c). The results demonstrate that inhibition of Arg-II
decreases monocyte adhesion activity to endothelial cells.
To further investigate the role of Arg-
II in proinﬂammatory responses of
macrophages, we examined the effect
of silencing Arg-II on the production of
proinﬂammatory mediators in response to
proinﬂammatory stimuli. In THP-1 cells,
both oxLDL (50 μg/mL, 24 hours) and LPS
(0.1 μg/mL, 8 hours) upregulated mRNA
expression of TNFα, MCP1, and IL6 in par-
allel with upregulation of Arg-II (Figure 2B).
Silencing Arg-II signiﬁcantly blunted the
upregulation by oxLDL or LPS at both the
mRNA (Figure 2B) and protein (Figure 2C)
levels, demonstrating an important role
of Arg-II in proinﬂammatory responses in
monocytes/macrophages. Because the
mRNA level reﬂects the protein level of the
inﬂammatory mediators, the proinﬂamma-
tory responses therefore were assessed by
monitoring mRNA levels for further studies.
To reinforce the aforementioned ﬁndings,
bone marrow cells were isolated from both
wild-type and Arg-II−/− mice26 and were
differentiated ex vivo into macrophages.
Gene expression of numerous proinﬂam-
matory mediators, including MCP1, TNFα,
IL6, matrix metalloproteinase (MMP) 14, and
iNOS, in response to LPS was reduced sig-
niﬁcantly in macrophages from Arg-II−/−
mice compared to the cells from wild-type
mice, as assessed by real-time qRT-PCR (Fig-
ure 3A). The presence and absence of Arg-
II gene expression validate the genotype of
the mice (Figure 3A, last graph). Of note,
LPS-induced MMP14 expression was lower
in Arg-II−/− macrophages than in wild-type
macrophages, although the difference was
not statistically signiﬁcant. In agreement with the results from
the cell lines shown in Figure 1A through 1C, no upregulation of
Arg-I expressionwas detected by qRT-PCR in themacrophages
upon LPS stimulation (Figure 3B).Most importantly, reintroduc-
tion ofmouse Arg-II cDNA into themacrophages fromArg-II−/−
mice not only restored but also enhanced the LPS-induced
gene expression of all the previously examined proinﬂamma-
tory mediators, including MMP14, to a much higher level than
in the cells from wild-type mice (Figure 3C). The ectopic ex-
pression of Arg-II was revealed by its mRNA level in the trans-
duced cells (Figure 3C, last graph). These results provide ﬁrm
evidence for a proinﬂammatory role of Arg-II in macrophages.
To evaluate the possible role of iNOS in LPS-induced proin-
ﬂammatory responses, macrophages from wild-type mice
were treated with L-NG-nitroarginine methyl ester (L-NAME;
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Figure 2. Silencing Arg-II suppressed proinﬂammatory functions of human monocytes. A, Silencing Arg-II in THP-1 monocytes decreased
monocyte adhesion onto activated endothelial cells. THP-1 cells were transduced with rAd/U6-LacZshRNA as control or with rAd/U6-hArg-IIshRNA.
Experiments were performed at day 4 after transduction. A-a, Immunoblotting revealed the efﬁcient knockdown of Arg-II expression. A-b,
Representative images of THP-1 adhesion onto TNFα-activated endothelial cells. A-c, Quantiﬁcation of the signals in A-b from 5 independent
experiments. Values are medians, and error bars represent 25th and 75th percentiles. HUVEC indicates human umbilical vein endothelial cells.
The Mann-Whitney test was used. B and C, Silencing Arg-II in human monocytes decreased the expression of proinﬂammatory genes. THP-1 cells
were transduced with rAd/U6-LacZshRNA as control or with rAd/U6-hArg-IIshRNA. At day 4 after transduction, cells were serum-starved in 0.2%
BSA-RPMI for 6 or 22 h, followed by stimulation with oxLDL (50 μg/mL) or LPS (0.1 μg/mL) for 24 or 8 h, respectively. Extracted RNA and
conditioned medium were then subjected to qRT-PCR (B) and enzyme-linked immunosorbent assay (C) analysis, respectively. Data shown are
mean±SEM from 6 independent experiments. *P<0.05, **P<0.01, and ***P<0.001 between the indicated groups.
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Figure 3. Targeted disruption of Arg-II suppressed proinﬂammatory functions of macrophages, and reintroduction of Arg-II into macrophages
from Arg-II−/− mice restored proinﬂammatory responses ex vivo. A and B, qRT-PCR analysis of LPS-induced (0.1 μg/mL, 22 h) mRNA expression
of proinﬂammatory mediators and Arg-II (A) as well as Arg-I (B) in bone marrow–derived macrophages from wild-type (wt) and Arg-II−/− mice.
Experiments were performed on day 7 after differentiation ex vivo. Cells were serum-starved for 6 h before addition of LPS. Data are mean±SEM
from 12 (untreated groups) or 6 (LPS-treated groups) individual animals. C, Macrophages differentiated from the bone marrow cells of Arg-II−/−
mice were transduced with rAd/CMV-LacZ as control or with rAd/CMV-Arg-II at day 6 after differentiation ex vivo. Two days after transduction,
cells were serum-starved for 6 h, stimulated with LPS (0.1 μg/mL, 22 h), and subjected to qRT-PCR analysis. Data shown are mean±SEM from 5
individual animals. *P<0.05, **P<0.01, and ***P<0.001 between the indicated groups.
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Figure 4. Inhibition of iNOS with L-NAME affected LPS-induced production of only IL6 but not of any other proinﬂammatory mediators in
macrophages. qRT-PCR analysis of LPS-induced (0.1 μg/mL, 22 h) mRNA expression of proinﬂammatory mediators in the absence or presence
of the NOS inhibitor L-NAME (5 mmol/L) in bone marrow–derived macrophages from wild-type mice. Nontreated cells were used as control (C).
Experiments were performed on day 7 after differentiation ex vivo. Cells were serum-starved for 4 h before addition of L-NAME (pretreatment for
2 h), followed by addition of LPS. Data shown are mean±SEM from 10 individual animals. *P<0.05, **P<0.01, and ***P<0.001 vs control or
between indicated groups.
5 mmol/L), which inhibits all the isoforms of NOS, including
iNOS, in macrophages. As shown in Figure 4, inhibition of iNOS
did not signiﬁcantly affect LPS-induced upregulation of the
proinﬂammatory mediators, including MCP1, TNFα, MMP14,
and iNOS itself, except for IL6, which was, however, signiﬁ-
cantly enhanced by L-NAME. The results suggest that iNOS
does not play a major role in upregulation of the proinﬂamma-
tory gene expression in macrophages. Rather, it exerts certain
antiinﬂammatory effects in the cells with regard to IL6 expres-
sion.
Arg-II Promotes Macrophage Proinﬂammatory
Responses Through Mitochondrial ROS
To evaluate the potential mechanism by which Arg-II promotes
macrophage proinﬂammatory responses, we then examined
the effect of Arg-II on mitochondrial ROS generation. As shown
in Figure 5A, the effect of reintroduction of the Arg-II gene in
Arg-II−/− macrophages on mitochondrial O2•− generation and
H2O2 level, as detected by MitoSox and H2DCF staining, re-
spectively, coincided with its effect on the proinﬂammatory
responses (Figure 3C). Remarkably, ectopic expression of the
Arg-II gene itself in Arg-II−/− macrophages, even in the absence
of LPS stimulation, enhanced generation ofmitochondrial O2•−
and H2O2 (Figure 5B), as well as expression of TNFα, IL6, and
MCP1 (Figure 5C). Moreover, scavenging both mitochondrial
O2•− and H2O2 with N-acetylcysteine (NAC, 5 mmol/L, 60
hours) (Figure 5B) prevented Arg-II–mediated cytokine produc-
tion, with no signiﬁcant effects on the ectopic Arg-II expression
(Figure 5C). These results demonstrate that Arg-II promotes
proinﬂammatory cytokine production in macrophages through
mitochondrial ROS.
Targeted Disruption of Arg-II Suppresses
Systemic Inﬂammation in Type II Diabetes
Mellitus
To further conﬁrm the role of Arg-II in macrophage inﬂam-
matory responses in vivo, we took advantage of Arg-II−/−
mice. Whole-body inﬂammation was induced by HF feeding
for 14 weeks, resulting in the low-grade inﬂammation model
of obesity-linked insulin resistance.32 Immunoblotting analy-
sis showed signiﬁcantly increased Arg-II protein levels in peri-
toneal macrophages of wild-type mice fed the HF diet as com-
pared to the levels of wild-typemice fed theNC diet (Figure 6A).
Adhesion assays were performedwith peritoneal macrophages
isolated from wild-type and Arg-II−/− mice fed either the NC or
the HF diet. As shown in Figure 6B, macrophages from obese
wild-type mice exhibited signiﬁcantly increased adhesion ac-
tivity as compared to those from lean animals, whereas the
increase in macrophage adhesion activity upon HF was pre-
vented in Arg-II−/− mice, which conﬁrms the proinﬂammatory
role of Arg-II observed in cultured human monocytes shown in
Figure 2A.
We then investigated whether the HF-induced chronic
inﬂammation in vivo can be inhibited by Arg-II gene deﬁciency.
Indeed, the obesity-associated macrophage inﬁltration in wild-
type animals on the HF diet, as assessed by confocal micro-
scopic immunoﬂuorescence staining of the pan-macrophage
marker F4/80 and the proinﬂammatory macrophage marker
CD11c, was suppressed in virtually all of the examined organs,
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Figure 5. Arg-II promoted macrophage proinﬂammatory responses through mitochondrial oxidative stress. A, Bone marrow–derived
macrophages were transduced and treated exactly as in Figure 3C and then were subjected to MitoSox or H2DCF staining for detection of
mitochondrial O2•− or H2O2 levels, respectively. Shown are representative images of experiments performed in macrophages from 5 individual
animals. The corresponding bar graphs show the quantiﬁcation of the relative ﬂuorescence intensity normalized by cell number. Data shown are
mean±SEM. B, Bone marrow–derived macrophages from Arg-II−/− mice were transduced with rAd/CMV-LacZ as control or with rAd/CMV-Arg-II
at day 6 after differentiation ex vivo. One day after transduction, cells were treated with NAC (5 mmol/L, 24 h) and then subjected to ROS
detection with MitoSox or H2DCF staining. Shown are representative images of experiments performed in macrophages from 6 individual animals.
The corresponding bar graphs show the quantiﬁcation of the relative ﬂuorescence intensity normalized by cell number. Data are mean±SEM. C,
Bone marrow–derived macrophages from Arg-II−/− mice were transduced as described in B. NAC (5 mmol/L) was added 12 h after transduction,
and cells were incubated for a further 60 h. Cells were serum-starved in 0.2% BSA-RPMI during the last 24 h in the absence or presence of NAC as
indicated. Total RNA was extracted 72 h after transduction and was subjected to qRT-PCR analysis. Data shown are mean±SEM from 8 individual
animals. Scale bar=50 μm. *P<0.05, **P<0.01, and ***P<0.001 between the indicated groups.
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Figure 6. Targeted disruption of Arg-II suppressed macrophage inﬂammation in obesity-linked insulin resistance / type II diabetes mellitus.
A, Immunoblotting analysis of Arg-II expression in peritoneal macrophages of wild-type (wt) mice fed NC or HF diet. Bar graph shows the
quantiﬁcation of the immunoblots. n=8, *P<0.05 between the 2 groups. B, Quantiﬁcation of the adhesion assay performed with peritoneal
macrophages from 4 different mouse groups as indicated. Data shown are mean±SEM obtained with 5 (NC group) or 6 (HF group) individual
mice. HUVEC indicates human umbilical vein endothelial cells. C, Representative confocal images of macrophage inﬁltration in epididymal fat as
assessed by immunoﬂuorescence staining of the parafﬁn-embedded sections with antibodies against the pan-macrophage marker F4/80 (red)
and the proinﬂammatory macrophage marker CD11c (green), followed by nuclei counterstaining with DAPI (blue). Images of F4/80 (left), CD11c
(middle), and merged (right) are shown. Scale bar=250 μm. D, Enlargement of the inset in C. Scale bar=50 μm. E, qRT-PCR analysis of mRNA
expression of the inﬂammatory markers in epididymal fat tissue. Data shown are mean±SEM from 5 (NC group) to 7 (HF group) individual animals.
*P<0.05, **P<0.01 between the indicated groups.
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Figure 7. Targeted disruption of Arg-II suppressed systemic macrophage inﬂammation in the HF-induced obesity-associated insulin resistance
mouse model. Representative photos of macrophage inﬁltration into various tissues, as assessed by confocal immunoﬂuorescence staining of
the parafﬁn-embedded sections with antibodies against the pan-macrophage marker F4/80 (red) and the proinﬂammatory macrophage marker
CD11c (green), followed by nuclei counterstaining with DAPI (blue). Shown are the representative merged images from 7 to 11 individual animals
of each group. Scale bar=50 μm. Quantiﬁcation of macrophage inﬁltration is expressed as a ratio of F4/80- or CD11c-positive cells to tissue
nuclei number and is presented in the corresponding graphs on the right. Values are medians, and error bars represent 25th and 75th percentiles.
Mann-Whitney test was used. *P<0.05, **P<0.01, and ***P<0.001 vs wild-type (wt).
including epididymal fat (Figure 6C), soleus muscle, liver, pan-
creas, heart, and kidney in the Arg-II−/− mice (Figure 7). The
macrophage inﬁltration in the fat tissue was characterized by
typical “crown-like” structures (Figure 6C and 6D). Moreover,
mRNA levels of the macrophage marker F4/80, CD11c, and
the inﬂammatory mediators MCP1 and IL6 in epididymal fat as
assessed by qRT-PCR were increased by HF feeding in wild-
type mice; the increase was prevented or markedly blunted
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in Arg-II−/− mice fed the HF diet (Figure 6E). Although TNFα
expression tended to be higher in obese wild-type than in lean
wild-type mice and lower in obese Arg-II−/− than in obese wild-
type mice, the difference did not reach statistical signiﬁcance
(Figure 6E). These data demonstrate a proinﬂammatory role of
Arg-II in type II diabetes mellitus in vivo.
Targeted Disruption of Arg-II Protects HF-Induced
Insulin Resistance
We further investigated whether suppressed chronic inﬂam-
mation in Arg-II−/− mice protects against obesity, glucose
intolerance, and insulin resistance. There was no signiﬁcant
difference in body weight development between wild-type and
Arg-II−/− mice fed the HF diet for 14 weeks (Figure 8A). HF
feeding increased plasma levels of cholesterol, triglyceride,
and insulin to a similar extent in wild-type and Arg-II−/− mice
(Figure 9). As expected, HF feeding caused hyperglycemia, glu-
cose intolerance, and impaired insulin sensitivity in wild-type
mice, as assessed by GTT and ITT. Glucose tolerance and in-
sulin sensitivity were improved signiﬁcantly in Arg-II−/− mice
fed the HF diet as compared to wild-type animals on the HF
diet, although they were not completely normalized (Figure 8B
and 8C). These results demonstrate that disruption of Arg-
II protects against type II diabetes mellitus independently of
obesity.
Targeted Disruption of Arg-II Reduces
Atherosclerosis
Next, we examined whether the decreased inﬂammation by
Arg-II gene disruption affects another important chronic in-
ﬂammatory disease: atherosclerosis.4,33 For this purpose, we
interbred Arg-II−/− mice with atherosclerosis-prone ApoE−/−
mice34 and obtained ApoE−/−Arg-II−/− mice. To accelerate
the atherosclerotic lesion formation, both ApoE−/−Arg-II+/+
and ApoE−/−Arg-II−/− mice (at the age of 10 weeks) were fed
either the HF diet or an atherogenic HC diet for 10 weeks.
The HF diet induced signiﬁcant atherosclerotic lesions in the
aortic roots (Figure 10A) of ApoE−/−Arg-II+/+ mice; this was
reduced markedly in ApoE−/−Arg-II−/− double-knockout mice
(the lesions in the thoracic and abdominal aortas on HF were
too small for quantiﬁcation, and the data are thus not pre-
sented). The proinﬂammatorymacrophage accumulation in the
plaque shown by F4/80 staining andCD11c/MMP14 (a vulner-
able plaque marker35) double-staining was markedly reduced
in ApoE−/−Arg-II−/− mice as compared to ApoE−/−Arg-II+/+
controls (Figure 10B). Furthermore, the atherogenic HC diet in-
ducedmore pronounced lesions through the whole aortas than
did the HF diet. The surface lesion size in aortas was signiﬁ-
cantly smaller in ApoE−/−Arg-II−/− mice than in ApoE−/−Arg-
II+/+ controls (Figure 10C). In addition, the size of necrotic
Figure 8. Improved glucose tolerance and insulin sensitivity in Arg-
II−/− mice. A, Growth curve of wild-type (wt) and Arg-II−/− mice on
NC or HF diets. GTT (B) and ITT (C) in lean and obese wild-type and
Arg-II−/− mice. Data shown are mean±SEM from 14 to 19 individual
animals. Area under the curve (AUC) is presented in the corresponding
graphs on the right. *P<0.05 between the indicated groups.
cores in advanced lesions of the aortic arch was markedly re-
duced in ApoE−/−Arg-II−/− mice as compared to ApoE−/−Arg-
II+/+ controls (Figure 10D). qRT-PCR analysis of plaque sam-
ples isolated from aortic arches showed decreased mRNA
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Figure 9. Blood parameters of wild-type (wt) and Arg-II−/− mice fed NC (n=9) or HF (n=17 or 18) diets for 14 weeks. Plasma samples were
prepared after 14 weeks of HF diet that started at the age of 7 weeks and after 6-h daytime food withdrawal.*P<0.05, **P<0.01, and ***P<0.001
between indicated groups.
levels of F4/80, MMP14, TNFα, and IL6 in ApoE−/−Arg-II−/−
mice as compared to ApoE−/−Arg-II+/+ mice (Figure 10E).
No signiﬁcant difference in plasma cholesterol or triglycerides
was observed between the 2 groups (Table 2). These re-
sults demonstrate that targeting Arg-II inhibits atherogenesis
and confers features of stable plaques independently of lipid
proﬁle.
Finally, we determined whether circulating monocytes con-
tribute to the reduced macrophage inﬂammation in the plaque
of ApoE−/−Arg-II−/− mice. For this purpose, in vivo adoptive
transfer experiments were carried out. In agreement with our in
vitro adhesion assay shown in Figure 2A, when ApoE−/−Arg-
II−/− double-knockout (dk) donor monocytes were injected,
the number of adoptively transferred monocytes found in the
atherosclerotic plaques of ApoE−/−Arg-II+/+ single-knockout
(sk) recipient mice was lower, as compared to the control con-
dition inwhich sk donormonocyteswere injected into the same
genotypic recipient mice (Figure 10F, dk→sk versus sk→sk).
Conversely, recipient dk mice, when compared to recipient sk
mice, accumulate fewer donor monocytes of either genotypic
mice. (Figure 10F, sk→dk versus sk→sk, and dk→dk versus
dk→sk). Of note, no additive reducing effect was observed
when both donor monocytes and the recipient mice are deﬁ-
cient in Arg-II (Figure 10F, dk→dk versus sk→dk). The results
demonstrate that both circulating monocytes and the vascular
microenvironment in ApoE−/−Arg-II−/− mice contribute to the
reduced macrophage inﬂammation in atherosclerotic lesions
in these animals.
Discussion
In the present study, we provide ﬁrm in vitro and in vivo evi-
dence showing that Arg-II plays a critical role in proinﬂamma-
tory responses of macrophages. Genetic targeted disruption of
Arg-II in mice suppresses the inﬂammatory responses, thereby
protecting against type II diabetes mellitus, insulin resistance,
and atherosclerosis.
The most important novel ﬁnding of our present study is the
functional characterization of the proinﬂammatory role of Arg-
II in macrophages. It is widely assumed that Arg-II shares its
function with Arg-I in macrophages, exerting an antiinﬂamma-
tory role. However, no experimental evidence has been pre-
sented so far, and results obtained from very limited stud-
ies on Arg-II in macrophages are contradictory. A previous
study proposed that Arg-II plays an antiinﬂammatory role in
macrophages,24 yet the assumption is based solely on results
showing that Arg-II gene is a direct target of liver X receptor,
which has been shown to exert inhibitory effects on expression
of inﬂammatory genes in macrophages. Another recently pub-
lished study, however, demonstrated that Arg-II–expressing
macrophages correlate with M1 phenotype and are associated
with more advanced atherosclerosis.17 The results from the
later study suggest that Arg-II could play a proinﬂammatory
role in macrophages. The opposing conclusions of these 2 re-
ports with regard to the role of Arg-II in macrophage function
are based on the correlations. We therefore investigated here
the causative effects of Arg-II on inﬂammatory responses of
macrophages.
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Figure 10. Targeted disruption of Arg-II reduced atherosclerosis in ApoE−/− mice. Mice were fed either HF (A and B) or HC (C, D, and E) diet for 10
weeks. A, Representative images showing Oil Red O staining of plaques in aortic roots of ApoE−/−Arg-II+/+ and ApoE−/−Arg-II−/− mice. Quantiﬁ-
cations of the lesions are presented in the graph below the stains. Data shown are medians with 25th and 75th percentiles from 8 animals of each
group. At least 7 equally spaced cryosections of aortic roots per mouse were evaluated. B, Representative confocal microscopic images showing
macrophage accumulation in the lesions stained with antibodies against F4/80 (red), or CD11c (green) and MMP14 (red). All sections were coun-
terstained with DAPI (blue). The merged images are shown. Scale bars=10 μm. Quantiﬁcations of the positive stained cells are presented in the
corresponding graphs on the right. Data shown aremedians with 25th and 75th percentiles from 8 animals of each group. C, Representative images
of Oil Red O staining of lesions in thoracic-abdominal aortas. Quantiﬁcations of the lesions are shown in the graph below the stain (n=18 of each
group). D, Hematoxylin-eosin staining of aortic arches of the 2mouse groups. Quantiﬁcations of necrotic core (indicated by #) are presented as per-
centage of the cell-free area to the total lesion area and are shown in the graph below the stain (n=10). At least 4 equally spaced sections permouse
were evaluated. E, qRT-PCR analysis of F4/80, MMP14, TNFα, and IL6 in the plaques isolated from aortic arches. Data shown are mean±SEM from
10 animals of each group. F, In vivo adoptive transfer. Labeled monocytes from donor ApoE−/−Arg-II+/+ (sk: groups 1 and 2) and ApoE−/−Arg-II−/−
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Table 2. Physiological and Plasma Parameters of
ApoE−/−Arg-II+/+ and ApoE−/−Arg-II−/− Mice Fed HC Diet
for 10 Weeks
ApoE−/−Arg-II+/+ ApoE−/−Arg-II−/−
Body weight, g
Begin 24.7±0.5 26.9±0.4*
Final 21.2±0.5 24.3±0.3*
Gain −3.8±0.8 −2.6±0.3
Total plasma cholesterol, mmol/L 66.9±2.4 65.9±2.5
Plasma triglycerides, mmol/L 0.81±0.04 0.96±0.07
Plasma samples were prepared after 10 weeks of HC diet, starting at the age of 10
weeks and after overnight food withdrawal.
*P<0.05 vs ApoE−/−Arg-II+/+ (n=18).
We went a step further by using in vitro and in vivo ge-
netic approaches and provided compelling evidence that Arg-
II promotes inﬂammatory responses in macrophages: (1) M1
activation of macrophages by LPS or differentiation of mono-
cytes into macrophages is accompanied by the upregulation
of Arg-II without having an effect on Arg-I expression in the
cells, which is in agreement with reports from the literature.31
Moreover, enhanced Arg-II expression also is observed in peri-
toneal macrophages from wild-type mice fed the HF diet as
compared to those of wild-type mice fed NC, demonstrating a
positive association of Arg-II with proinﬂammatory responses
in macrophages in this chronic inﬂammation animal model
of type II diabetes mellitus. (2) Silencing the Arg-II gene in
human monocyte/macrophage cell lines decreases cell adhe-
sion to endothelial cells and the production of proinﬂamma-
tory mediators in response to oxLDL or LPS at both the mRNA
and protein levels. (3) The adhesion activities of macrophages
from HF-fed Arg-II−/− mice to endothelial cells also are de-
creased signiﬁcantly compared to those from obese wild-type
control mice. It is noticeable that no difference in cell adhe-
sion is observed under NC conditions between wild-type and
Arg-II−/− mice, which does not seem in line with the observa-
tions in the human monocytic cell line (Figure 2A). This might
be due to either the species difference36,37 or the functional
differences between monocytes and macrophages.38 Never-
theless, under HF diet conditions, cell adhesion was reduced
in Arg-II−/− mice, which indicates that Arg-II indeed is involved
in monocyte/macrophage adhesion, particularly under patho-
logical conditions. (4) LPS-induced upregulation of numer-
ous proinﬂammatory mediators, including MCP1, TNFα, IL6,
MMP14, and iNOS, is signiﬁcantly suppressed in macrophages
isolated from Arg-II−/− mice as compared with those from
wild-type mice. (5) Most importantly, reintroduction of the Arg-
II gene into macrophages from Arg-II−/− mice restores and
even enhances the LPS-stimulated expression of the proin-
ﬂammatory genes compared to the levels in cells from wild-
type mice. (6) Ectopic expression of Arg-II itself in Arg-II−/−
macrophages, in the absence of LPS stimulation, increases
expression of the proinﬂammatory genes. (7) Systemic proin-
ﬂammatory macrophage inﬁltration in various organs and ex-
pression of proinﬂammatory mediators in adipose tissues in
a chronic inﬂammation animal model of type II diabetes mel-
litus are reduced signiﬁcantly in obese Arg-II−/− mice. (8) In
another chronic inﬂammation animal model (atherosclerotic
ApoE−/− mice), targeted disruption of Arg-II not only decreases
lesion size but also confers characteristics of stable plaque—
namely, decreased macrophage accumulation and production
of proinﬂammatory mediators, MMP14, and necrotic cores in
the plaque. (9) In vivo adoptive transfer experiments reveal
that Arg-II deﬁciency in circulating monocytes (ApoE−/−Arg-
II−/− donor monocytes) signiﬁcantly reduces their inﬁltration
into the plaque of recipient ApoE−/−Arg-II+/+ mice, reinforcing
our observation in the in vitro adhesion assay and indicating
that the Arg-II deﬁciency in circulating monocytes contributes
to the phenotype in ApoE−/−Arg-II−/− mice. The decreased
inﬁltration of donor monocytes from either genotype into the
plaque of recipient ApoE−/−Arg-II−/− mice reﬂects and con-
ﬁrms the fact that there is less inﬂammation in the vascu-
lar microenvironment of the ApoE−/−Arg-II−/− mice than the
ApoE−/−Arg-II+/+ mice. Collectively, these data provide for
the ﬁrst time in vitro and in vivo novel evidence demonstrating
that Arg-II plays a critical role in proinﬂammatory responses in
monocytes/macrophages.
The function of arginase is considered to be closely related
to its involvement in the regulation of nitric oxide production
through competition with iNOS for their common substrate
L-arginine, which results in decreased nitric oxide production
in macrophages.39 iNOS has been considered to play a proin-
ﬂammatory role in M1 macrophages upon LPS stimulation.
Our results, however, do not support a major role of iNOS in
mediating proinﬂammatory responses in macrophages with
regard to proinﬂammatory gene expression. If Arg-II regulated
inﬂammatory responses through iNOS, inhibition of iNOS with
L-NAME would have a substantial impact on Arg-II–mediated
Figure 10. (continued) (dk: groups 3 and 4) mice were injected into recipient ApoE−/−Arg-II+/+ (groups 1 and 3: sk→sk and dk→sk,
respectively) and ApoE−/−Arg-II−/− (groups 2 and 4: sk→dk and dk→dk, respectively) mice. Data are presented as percentage change to the
sk→sk control group. The number of ﬂuorescent macrophages counted in atherosclerotic lesions of the control group (sk→sk) is 61.29±11.46
(n=7 for groups 1 and 3; n=6 for groups 2 and 4). *P<0.05; ***P<0.001 between the indicated groups.
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proinﬂammatory cytokine gene expression. This is not the
case, however.Wedonot observe signiﬁcant effects of L-NAME
on the expression of themajority of the proinﬂammatory genes
in macrophages, except IL6, which is signiﬁcantly enhanced by
inhibition of iNOS with L-NAME. This result is consistent with
a previous report31 and suggests a negative regulatory role of
iNOS on IL6 expression. Moreover, iNOS is not induced by LPS
in the humanmacrophage cell line THP-1, yet Arg-II silencing in
these cells still inhibits macrophage adhesion activity and ex-
pression of the proinﬂammatory genes. The difference in iNOS
expression between human and murine macrophages is in
agreement with several other studies.36,37 The dissociation of
arginase activity from iNOS has been reported by several stud-
ies, showing that alteration of arginase activity in macrophages
is not necessarily associated with functional changes in
iNOS.40–43
Evidence has been presented that ROS, especially the
mitochondrial ROS, promote production of proinﬂammatory
cytokines.9–11 In an attempt to evaluate the molecular mecha-
nisms of Arg-II–mediated, iNOS-independent proinﬂammatory
responses in macrophages, we demonstrated that the en-
hancedmitochondrial ROS are responsible for Arg-II–mediated
proinﬂammatory responses in macrophages. This conclusion
is supported by the following evidence: First, in Arg-II−/−
macrophages, LPS-induced production of mitochondrial O2•−
and H2O2 is markedly enhanced by reintroduction of the Arg-II
gene. In addition, ectopic expression of the Arg-II gene it-
self in Arg-II−/− macrophages, even in the absence of LPS
stimulation, also enhances generation of mitochondrial O2•−
and H2O2. Second, the production of mitochondrial O2•− and
H2O2 parallels the production of proinﬂammatory cytokines.
Third, treatment of bone marrow–derived macrophages with
the antioxidant NAC, which abolishes production of mitochon-
drial O2•− and H2O2, signiﬁcantly reduces Arg-II–mediated
inﬂammatory responses. Given that Arg-II is a mitochondrial
enzyme,44 a pressing goal for the future will be to investigate
how Arg-II affects mitochondrial function leading to mitochon-
drial ROS production.
Chronic macrophage inﬂammation is an important
pathogenic mechanism shared by obesity-linked insulin resis-
tance and atherosclerosis. In support of these notions, we
show in the present study that targeted disruption of Arg-II
suppresses macrophage inﬂammation, contributing to protec-
tion against disease development in animal models. In the
obesity-linked insulin resistance model, targeted disruption
of Arg-II in mice improves glucose homeostasis and protects
against hyperglycemia in obese mice fed HF diet. It is of note
that disruption of Arg-II does not affect plasma concentra-
tion of cholesterol, triglycerides, or insulin, nor does it affect
body weight gain, which suggests that Arg-II ablation protects
against type II diabetes mellitus independently of the plasma
parameters and obesity, which can be attributed to decreased
chronic systemic inﬂammation in insulin-responsive tissues.
This is in agreement with a previous study reporting that ab-
lation of the proinﬂammatory macrophages normalizes insulin
sensitivity in obese insulin-resistant animals without affecting
body weight gain.2
In the atherosclerosis model, genetic ablation of Arg-II re-
duces atherosclerotic plaque formation and confers features
of stable plaques: reduced lesion size, decreased necrotic
core, macrophage accumulation, and proinﬂammatory medi-
ators in the plaque. The results of genetic ablation of Arg-II on
atherosclerosis development in our present study are in agree-
mentwith a recent report by Ryoo et al.25 It is important to point
out that in their study, a pharmacological approach was taken
to assess the effect of an arginase inhibitor on atheroscle-
rosis development in ApoE−/− mice, whereas Arg-II−/− mice
were used to evaluate the role of Arg-II in atherogenic diet–
induced endothelial dysfunction. In our study, we have inves-
tigated for the ﬁrst time the role of Arg-II in atherosclero-
sis with a genetic approach, by generating ApoE−/−Arg-II−/−
double-knockout mice. Moreover, we demonstrated that tar-
geting Arg-II, in addition to preserving endothelial function,
also suppresses macrophage inﬂammation and contributes
to reduced atherosclerosis in ApoE−/− mice. Our study thus
adds a novel perspective to the linkage between Arg-II and
atherosclerosis.
In summary, our study demonstrates that Arg-II plays a crit-
ical role in macrophage proinﬂammatory responses through
mitochondrial ROS production, contributing to the develop-
ment of both type II diabetes mellitus and atherosclerosis.
Given that general inhibitors of arginase cause deleterious
hyperammonemia due to inhibition of hepatic Arg-I and that
no speciﬁc inhibitors of extrahepatic Arg-II are available, our
study could open a new therapeutic avenue for developing
speciﬁc medications targeting Arg-II for treatment of chronic
inﬂammatory diseases, including type II diabetes mellitus and
atherosclerosis.
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